Neurocode

Neurocode is a private, commercial-stage diagnostics company founded in 2018, specializing in advanced testing for neurological and neuroimmunological disorders. Its core offerings include a proprietary plasma p-Tau217 assay for Alzheimer's disease and an exclusive, licensed live cell-based assay for AChR antibodies in myasthenia gravis. Operating a CAP/CLIA-certified lab, the company generates revenue by providing these high-sensitivity tests to clinicians, researchers, and clinical trial sponsors. Neurocode positions itself as a leader in niche neurology diagnostics through technological exclusivity and a focused service model.

Proprietary blood-based biomarker assays (e.g., p-Tau217) for neurodegeneration and exclusive live cell-based assay (CBA) technology licensed from Oxford University for neuroimmunology antibody detection.

In Alzheimer's diagnostics, Neurocode competes with large reference labs (Quest, Labcorp), specialized companies (C2N Diagnostics, ALZpath), and in-development efforts from numerous biopharma and diagnostic firms. In neuroimmunology testing, it faces competition from other major reference laboratories offering comprehensive antibody panels, though its exclusive live CBA provides a key differentiation in sensitivity for myasthenia gravis.